BRCA1 and cystic fibrosis: For a common disease like cystic fibrosis, the estimated clinical sensitivity was 99.90%, with PPV, specificity, and NPV all >99.9% (Figure 3), comparable to levels of clinical validity reported for hereditary cancer screening of BRCA1/2.